Compare BioNTech SE - ADR (BNTX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Williams Companies Inc — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while Williams Companies Inc trades at $73.59 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 3.8× BioNTech SE - ADR's market cap, and Williams Companies Inc pays a 2.9% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WMB | |
|---|---|---|
Market Cap | $23.31B | $88.45B |
Sector | Health | Energy |
52-Week High | $119.34 | $79.40 |
52-Week Low | $83.89 | $56.51 |
Enterprise Value | $6.60B | $119.07B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
WMB trades at $73.72, up 2.6% today, with a bullish technical signal and strong analyst support. The company reported mixed quarterly earnings but raised full-year EBITDA guidance to $8.4 billion following its $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast footprint. Fundamentals show robust profitability with a 25.18% net income margin and 24.02% ROE, though valuation multiples like a P/E of 28.81 appear elevated.
The outlook is positive, driven by growth initiatives and stable cash flows, but risks include execution of the large acquisition and sensitivity to energy demand. With a consensus price target of $87.14 implying 18% upside, the stock offers growth potential tempered by integration challenges and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
